1. A pharmaceutical composition for use in the prevention and / or treatment of a neurodegenerative disease, said composition comprising desProexendin-4 (1-39) -Lys-NHi / or a pharmaceutically acceptable salt thereof and, optionally, a pharmaceutically acceptable carrier, adjuvant and / or excipient. 2. A pharmaceutical composition for use according to claim 1, wherein the neurodegenerative disease is associated with oxidative stress, loss of neurite integrity, apoptosis, loss of neurons and / or inflammatory response. A pharmaceutical composition for use according to claim 1, wherein desProexendin-4 (1-39) -Lys-NHi / or a pharmaceutically acceptable salt thereof is prepared for parenteral administration. A composition intended for use according to claim 1 or 2, wherein the neurodegenerative disease is associated with a cognitive impairment. 5. The composition intended for use according to claim 1 or 2, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy (PSP), multiple systemic atrophy (MSA), dementia with Levi bodies, dementia in Parkinson's disease , epilepsy, stroke, Huntington's chorea, cerebral hypoxia, multiple sclerosis and peripheral neuropathy. 6. A composition intended for use according to claim 5, wherein peripheral neuropathy is associated with diabetes mellitus. The composition intended for use according to claim 5, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease and stroke. The composition intended for use according to p.1. Фармацевтическая композиция, предназначенная для применения при предупреждении и/или лечении нейродегенеративного заболевания, причем указанная композиция содержит desProэксендин-4(1-39)-Lys-NHи/или его фармацевтически приемлемую соль и, необязательно, фармацевтически приемлемый носитель, адъювант и/или вспомогательное вещество.2. Фармацевтическая композиция, пре
